MedTrace Logo

Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey

NCT01322932 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2015-12-22

No results posted yet for this study

Summary

The purpose of this study is to assess adherence, tolerability and satisfaction of each eligible HIV subjects switching from a two- or three-pill tenofovir-emtricitabine-efavirenz (TDF-FTC-EFV) to a one-pill TDF-FTC-EFV treatment.

Conditions

  • HIV Infection

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Vaudois

    collaborator OTHER

  • Swiss HIV Cohort Study

    collaborator NETWORK

  • Gilead Sciences

    collaborator INDUSTRY

  • Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

    lead OTHER

Principal Investigators

  • Matthias Cavassini, M.D · Centre Hospitalier Universitaire Vaudois

  • Marie-Paule Schneider, PhD · Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

  • Olivier Bugnon, Professor · Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

  • Aurélie Gertsch, PhD Student · Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-10-31
Completion
2012-02-29

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01322932 on ClinicalTrials.gov